$NKTR
NEKTAR THERAPEUTICS

2017 Q1 Form 10-Q Financial Statement

#000156459017010026 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q1
Revenue $24.73M $37.45M $58.88M
YoY Change -58.0% -4.88% -45.88%
Cost Of Revenue $6.131M $6.604M $8.870M
YoY Change -30.88% -21.04% 5.05%
Gross Profit $18.60M $30.85M $50.01M
YoY Change -62.81% -0.52% -50.17%
Gross Profit Margin 75.21% 82.37% 84.94%
Selling, General & Admin $12.00M $12.80M $10.20M
YoY Change 17.65% -3.03% -0.97%
% of Gross Profit 64.53% 41.5% 20.4%
Research & Development $61.06M $50.23M $49.27M
YoY Change 23.93% 6.57% 4.8%
% of Gross Profit 328.32% 162.85% 98.51%
Depreciation & Amortization $4.000M $3.900M $3.700M
YoY Change 8.11% 2.63% 23.33%
% of Gross Profit 21.51% 12.64% 7.4%
Operating Expenses $61.06M $50.23M $49.27M
YoY Change 23.93% 6.57% 4.8%
Operating Profit -$54.44M -$32.15M -$9.484M
YoY Change 473.99% 9.47% -122.03%
Interest Expense $5.402M -$9.600M $5.677M
YoY Change -4.84% -10.28% 36.11%
% of Operating Profit
Other Income/Expense, Net -$9.296M -$9.847M
YoY Change -5.6% 9.29%
Pretax Income -$63.73M -$41.80M -$19.33M
YoY Change 229.69% -22.74% -156.8%
Income Tax $133.0K $400.0K $167.0K
% Of Pretax Income
Net Earnings -$63.87M -$42.20M -$19.50M
YoY Change 227.55% -22.05% -157.65%
Net Earnings / Revenue -258.27% -112.68% -33.11%
Basic Earnings Per Share -$0.42 -$0.28 -$0.14
Diluted Earnings Per Share -$0.42 -$0.28 -$0.14
COMMON SHARES
Basic Shares Outstanding 153.8M 152.8M 135.8M
Diluted Shares Outstanding 135.8M

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $358.5M $389.1M $288.3M
YoY Change 24.35% 25.96% -4.16%
Cash & Equivalents $23.48M $59.64M $72.50M
Short-Term Investments $335.0M $329.5M $215.8M
Other Short-Term Assets $7.900M $10.36M $5.600M
YoY Change 41.07% 5.59% -8.08%
Inventory $13.00M $11.11M $11.30M
Prepaid Expenses
Receivables $1.600M $15.68M $39.70M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $381.0M $426.3M $344.8M
YoY Change 10.5% 21.77% -0.72%
LONG-TERM ASSETS
Property, Plant & Equipment $66.64M $65.60M $69.90M
YoY Change -4.66% -8.04% 0.91%
Goodwill $76.50M $76.50M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $3.500M
YoY Change
Other Assets $865.0K $817.0K $700.0K
YoY Change 23.57% 8.36% -88.62%
Total Long-Term Assets $147.5M $142.6M $147.1M
YoY Change 0.26% -4.02% -3.17%
TOTAL ASSETS
Total Short-Term Assets $381.0M $426.3M $344.8M
Total Long-Term Assets $147.5M $142.6M $147.1M
Total Assets $528.5M $568.9M $491.9M
YoY Change 7.44% 14.08% -1.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.951M $2.816M $2.300M
YoY Change 202.22% 19.17% -54.22%
Accrued Expenses $29.60M $35.10M $31.10M
YoY Change -4.82% 55.31% 277.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.900M $4.800M
YoY Change -39.58% -11.11%
Total Short-Term Liabilities $78.52M $72.22M $65.95M
YoY Change 19.06% 17.92% -12.59%
LONG-TERM LIABILITIES
Long-Term Debt $245.5M $243.5M $245.5M
YoY Change 0.0% 0.29% 89.72%
Other Long-Term Liabilities $4.116M $5.000M $6.536M
YoY Change -37.03% -48.67% -61.78%
Total Long-Term Liabilities $4.116M $5.000M $6.536M
YoY Change -37.03% -48.67% -61.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $78.52M $72.22M $65.95M
Total Long-Term Liabilities $4.116M $5.000M $6.536M
Total Liabilities $483.7M $480.7M $492.2M
YoY Change -1.71% -2.33% 16.65%
SHAREHOLDERS EQUITY
Retained Earnings -$2.085B -$2.021B -$1.887B
YoY Change 10.5% 8.22% 7.67%
Common Stock $2.132B $2.111B $1.889B
YoY Change 12.88% 12.55% 3.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.75M $88.13M -$275.0K
YoY Change
Total Liabilities & Shareholders Equity $528.5M $568.9M $491.9M
YoY Change 7.44% 14.08% -1.47%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q1
OPERATING ACTIVITIES
Net Income -$63.87M -$42.20M -$19.50M
YoY Change 227.55% -22.05% -157.65%
Depreciation, Depletion And Amortization $4.000M $3.900M $3.700M
YoY Change 8.11% 2.63% 23.33%
Cash From Operating Activities -$34.60M -$52.40M -$23.60M
YoY Change 46.61% -30.23% -137.28%
INVESTING ACTIVITIES
Capital Expenditures $4.089M -$2.700M $1.679M
YoY Change 143.54% 8.0% 58.55%
Acquisitions
YoY Change
Other Investing Activities -$9.000M -$139.4M $37.90M
YoY Change -123.75% 2865.96% -30.07%
Cash From Investing Activities -$13.10M -$142.1M $36.20M
YoY Change -136.19% 1873.61% -31.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $189.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.20M 190.9M 4.400M
YoY Change 154.55% 60.29% 633.33%
NET CHANGE
Cash From Operating Activities -34.60M -52.40M -23.60M
Cash From Investing Activities -13.10M -142.1M 36.20M
Cash From Financing Activities 11.20M 190.9M 4.400M
Net Change In Cash -36.50M -3.600M 17.00M
YoY Change -314.71% -109.78% -85.48%
FREE CASH FLOW
Cash From Operating Activities -$34.60M -$52.40M -$23.60M
Capital Expenditures $4.089M -$2.700M $1.679M
Free Cash Flow -$38.69M -$49.70M -$25.28M
YoY Change 53.05% -31.54% -140.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
3493000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65601000
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
0
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66642000
CY2016Q4 us-gaap Goodwill
Goodwill
76501000
CY2017Q1 us-gaap Goodwill
Goodwill
76501000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
817000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
865000
CY2016Q4 us-gaap Assets
Assets
568871000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6951000
CY2017Q1 us-gaap Assets
Assets
528486000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2816000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18280000
CY2017Q1 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
7443000
CY2016Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
7958000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6576000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4711000
CY2017Q1 us-gaap Interest Payable Current
InterestPayableCurrent
4090000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4198000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14352000
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2391000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4499000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
78515000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
72222000
CY2017Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
243900000
CY2017Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
6663000
CY2016Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
6535000
CY2017Q1 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
6092000
CY2016Q1 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
34187000
CY2017Q1 us-gaap Revenues
Revenues
24728000
CY2016Q1 us-gaap Revenues
Revenues
58882000
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6131000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8870000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61058000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49268000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11976000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10228000
CY2016Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
243464000
CY2016Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
105950000
CY2017Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1609000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2223000
CY2017Q1 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
103931000
CY2017Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2909000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2908000
CY2017Q1 nktr Liability For Refundable Upfront Payment
LiabilityForRefundableUpfrontPayment
12500000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11463000
CY2016Q4 nktr Liability For Refundable Upfront Payment
LiabilityForRefundableUpfrontPayment
12500000
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24192000
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4116000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
51887000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5000000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
15000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2111483000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2131698000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2363000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1849000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2021010000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2085115000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
88125000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
44749000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
568871000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
528486000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q1 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2016Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153212000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153212000
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154731000
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154731000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
51666000
CY2017Q1 us-gaap Liabilities
Liabilities
483737000
CY2016Q4 us-gaap Liabilities
Liabilities
480746000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
79165000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
68366000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-54437000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9484000
CY2017Q1 us-gaap Interest Expense
InterestExpense
5402000
CY2016Q1 us-gaap Interest Expense
InterestExpense
5677000
CY2017Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
4552000
CY2016Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5045000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
658000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
875000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9296000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9847000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63733000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19331000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
133000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
167000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-63866000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-19498000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
153666000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135793000
CY2015Q3 nktr Damage Claim For Alleged Unpaid Licensing Fee
DamageClaimForAllegedUnpaidLicensingFee
1500000
CY2017Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2016Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2017Q1 nktr Potential Development Milestones
PotentialDevelopmentMilestones
147000000
CY2017Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1518605
CY2016Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
862546
CY2017Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
362016000
CY2017Q1 us-gaap Senior Notes
SeniorNotes
250000000
CY2017Q1 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
254500000
CY2017Q1 us-gaap Capital Lease Obligations
CapitalLeaseObligations
4500000
CY2017Q1 nktr Number Of Operating Business Segment
NumberOfOperatingBusinessSegment
1
CY2016Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
389102000
CY2017Q1 nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
Two years or less
CY2017Q1 nktr Debt Investment Maturity Date Description
DebtInvestmentMaturityDateDescription
One year or less
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
335607000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
330713000
CY2017Q1 nktr Cash And Restricted Cash
CashAndRestrictedCash
4239000
CY2016Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
4355000
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1880000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2055000
CY2017Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9767000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7311000
CY2017Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1369000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1743000
CY2017Q1 nktr Estimated Annual Interest Rate On Royalty Liability
EstimatedAnnualInterestRateOnRoyaltyLiability
0.17

Files In Submission

Name View Source Status
0001564590-17-010026-index-headers.html Edgar Link pending
0001564590-17-010026-index.html Edgar Link pending
0001564590-17-010026.txt Edgar Link pending
0001564590-17-010026-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nktr-10q_20170331.htm Edgar Link pending
nktr-20170331.xml Edgar Link completed
nktr-20170331.xsd Edgar Link pending
nktr-20170331_cal.xml Edgar Link unprocessable
nktr-20170331_def.xml Edgar Link unprocessable
nktr-20170331_lab.xml Edgar Link unprocessable
nktr-20170331_pre.xml Edgar Link unprocessable
nktr-ex311_9.htm Edgar Link pending
nktr-ex312_8.htm Edgar Link pending
nktr-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending